explore -WSS

explore

author：hotspot 2025-09-29 18:16:06 - browse：4855

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Google and Epic fight stronger regulation of AI in health care

explore

WSS

Anthos stroke drug appears safer than common blood thinner

Doctors find melanoma drugs effective against rare brain cancer

Doctors find melanoma drugs effective against rare brain cancer

Congress must reauthorize a committee to support older Americans

Sanofi seeks simpler, safer CRISPR sickle cell cure

Readout LOUD podcast: A CRISPR milestone, biotech mixology

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

DIEP, the 'gold standard' of breast reconstruction, is under threat

At Orexo, a ‘turning point’ for everything but digital health

Continuity nursing helped my family in our darkest PICU moments

How dance can help nurses traumatized by Covid

Virginia high school admissions case could be legal follow

Poor hospice wound care hurts patients and families

At least 13 dead in Texas as scorching temps continue

Weight loss drug costs may need more research, senator suggests

hotspot

Astellas still sees hope in its gene therapy after four deaths

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

NYU radiologists take on the challenge of expensive MRI machines

In key trial, Verve's treatment lowers cholesterol levels in patients

Medicare has a new plan to address drug shortages

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

focus

explore

leisure time

entertainment